Literature DB >> 24037498

Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma.

George A Alexiou1, Evrysthenis Vartholomatos, Spyridon Voulgaris.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24037498     DOI： 10.1007/s11060-013-1240-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

1.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

Review 2.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.

Authors:  Graeme J K Guthrie; Kellie A Charles; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Stephen J Clarke
Journal:  Crit Rev Oncol Hematol       Date:  2013-04-17       Impact factor: 6.312

3.  The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme.

Authors:  R M Bambury; M Y Teo; D G Power; A Yusuf; S Murray; J E Battley; C Drake; P O'Dea; N Bermingham; C Keohane; S A Grossman; E J Moylan; S O'Reilly
Journal:  J Neurooncol       Date:  2013-06-19       Impact factor: 4.130
  3 in total
  8 in total

1.  Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme.

Authors:  Marta Lopes; Bruno Carvalho; Rui Vaz; Paulo Linhares
Journal:  J Neurooncol       Date:  2017-10-26       Impact factor: 4.130

2.  Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.

Authors:  Shirin Karimi; Manav V Vyas; Lior Gonen; Raha Tabasinejad; Quinn T Ostrom; Jill Barnholtz-Sloan; Suganth Suppiah; Gelareh Zadeh; Kenneth Aldape
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

3.  Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival.

Authors:  John K Wiencke; Devin C Koestler; Karl T Kelsey; Margaret R Wrensch; Brock C Christensen; Lucas A Salas; Joseph L Wiemels; Ritu P Roy; Helen M Hansen; Terri Rice; Lucie S McCoy; Paige M Bracci; Annette M Molinaro
Journal:  Clin Epigenetics       Date:  2017-02-02       Impact factor: 6.551

4.  Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.

Authors:  Peng-Fei Wang; Hong-Wang Song; Hong-Qing Cai; Ling-Wei Kong; Kun Yao; Tao Jiang; Shou-Wei Li; Chang-Xiang Yan
Journal:  Oncotarget       Date:  2017-07-25

5.  Prognostic role of neutrophil lymphocyte ratio in patients with glioma.

Authors:  Jing Zhang; Sunfu Zhang; Yanlin Song; Min He; Qingqing Ren; Chaoyue Chen; Zhiyong Liu; Yunhui Zeng; Jianguo Xu
Journal:  Oncotarget       Date:  2017-07-22

6.  Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Authors:  Aurélie Bertaut; Caroline Truntzer; Rachid Madkouri; Coureche Guillaume Kaderbhai; Valentin Derangère; Julie Vincent; Bruno Chauffert; Marie Hélene Aubriot-Lorton; Wahlid Farah; Klaus Luc Mourier; Romain Boidot; Francois Ghiringhelli
Journal:  Oncotarget       Date:  2016-10-25

7.  Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma.

Authors:  Alicia Martínez-González; Raquel Cabrera; Marta Lloret; Pedro C Lara
Journal:  Cancer Drug Resist       Date:  2020-08-07

8.  Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome.

Authors:  Celine Garrett; Therese M Becker; David Lynch; Joseph Po; Wei Xuan; Kieran F Scott; Paul de Souza
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.